Longwood Capital Partners »

Avalyn Pharma shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Avalyn Pharma shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Avalyn Pharma

Tip: Access up to 7 years of quarterly data

All positions including Avalyn Pharma held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Avalyn Pharma by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.8M 115k 32.92

More positions owned by Longwood Capital Partners

Praxis Precision Medicines I Com New (PRAX)
Aadi Bioscience (WHWK)
Tango Therapeutics (TNGX)
Sutro Biopharma (STRO)
Arrivent Biopharma (AVBP)
4d Molecular Therapeutics In (FDMT)
Bright Minds Biosciences Com New (DRUG)
Ocular Therapeutix (OCUL)
Erasca (ERAS)
Surrozen Com New (SRZN)
Argen Se - Sponsored Adr (ARGX)
Moonlake Immunotherapeutics Class Ord A (MLTX)
Design Therapeutics (DSGN)
Minerva Neurosciences Com New (NERV)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Longwood Capital Partners

Top funds holding Avalyn Pharma

FMR
Novo A/S
Sr One Capital Management
Perceptive Advisors
Suvretta Capital Management
NVP Associates
Wellington Management Company
Catalio Capital Management
Eventide Asset Management
Bellevue Group
BlackRock
Pivotal bioVenture Partners Investment Advisor
Citadel Advisors
Andera Partners
Jennison Associates

View all funds holding Avalyn Pharma